Drug intelligence / Profile preview

C-terminal fibroblast growth factor 23 fragment

Development stage
Preclinical
Lead developer
Généthon
Modality
Peptides
Administration
Intravenous, Subcutaneous, Intraperitoneal
01

Overview

C-terminal fibroblast growth factor 23 fragment (cFGF23) is a naturally occurring peptide fragment generated by the proteolytic cleavage of intact fibroblast growth factor 23 (iFGF23) at its RXXR motif. It acts as a competitive antagonist of iFGF23 by binding to the binary FGF receptor (FGFR)-Klotho complex, thereby blocking downstream FGF23 signaling. In preclinical models, cFGF23 has been investigated as a therapeutic agent to treat bone mineralization defects, restore hematopoietic stem cell (HSC) bone marrow niche function in beta-thalassemia, and mitigate kidney inflammation and cardiomyopathy associated with pathological FGF23 excess.

Other names
C-terminal FGF23 fragmentC-terminal FGF23 peptideFGF23 C-terminal tail peptideFGF-23 C-terminal tail peptideFGF 23 C-terminal tail peptideFGF23 C-tail peptideFGF-23 C-tail peptideFGF 23 C-tail peptideFGF23 blocking peptideFGF-23 blocking peptideFGF 23 blocking peptidecarboxyl-terminal FGF23 peptidecFGF23cFGF-23cFGF 23
02

Targets

FGFR1 (Fibroblast growth factor receptor 1)KL (Klotho Protein)

Beyond the preview

Go deeper on C-terminal fibroblast growth factor 23 fragment.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on C-terminal fibroblast growth factor 23 fragment.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call